NCT05546424 is a clinical trial of EMRESERVA in Cognitive Change, sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla.

Who is sponsoring NCT05546424?

NCT05546424 is sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla.

What drugs are being tested in NCT05546424?

Interventions in NCT05546424: EMRESERVA.

What condition does NCT05546424 study?

NCT05546424 studies Cognitive Change.

Is NCT05546424 still recruiting?

NCT05546424 is currently completed. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT05546424

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis

Completed Last updated 7 February 2024

What this trial tests

trial testing EMRESERVA in Cognitive Change in 58 participants. Completed in 30 November 2023.

Timeline

19 May 2022

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Status	Completed
Study type	OBSERVATIONAL
Enrollment	58
Start date	19 May 2022
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	1 location across Spain

Drugs / interventions tested

EMRESERVA

Conditions studied

Cognitive Change — all drugs for Cognitive Change →

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — full company profile →

Who can join

Adults 18 to 55, any sex, with Cognitive Change. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple Sclerosis(MS) is an immunological degenerative disease that affects central nervous system causing cognitive impairment, which is one of the most disabling symptoms in MS. Cognitive reserve may influence manifestations of symptoms of cognitive impairment in MS patients and could justify interindividual differences. Cognitive reserve hypothesis raises that enriching life experiences creates a higher capacity and efficiency of neural networks and protects against cognitive decline in neurological diseases. Scientific evidence demonstrates that older adults with a higher educational,occupational attainment or engagement in cognitively stimulating leisure activities have a reduced risk of dementia.Systematic reviews report little efficacy of pharmacological and behavioral treatments impairment in cognitive functions in MS patients . As such, best treatment of cognitive impairment in MS may be a proactive prevention of cognitive decline in first place Through the application of the EM-Reserva program our goal is to evaluate if it is possible to improve cognitive skills of patients with MS without cognitive impairment versus those who undergo non-specific cognitive exercises. In the short and medium term, EM-Reserva program could improve cognitive performance and delay the appearance or modulate the severity of cognitive impairment in the course of the disease

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Implementation of a Program to Enhance Cognitive Reserve in Patients With Multiple Sclerosis (EM Reserva Program).
Insenser MB, Ruiz RL, Borges Guerra M, Domínguez EV, et al · · 2026 · PMID 42052787 · DOI 10.31083/rn48330

Verify or expand the search:

Other recruiting trials for Cognitive Change

Currently open trials in the same condition.

NCT07147894 — Executive Function Training for Children and Adolescents · NA · recruiting
NCT07383324 — Heat Stress in Individuals With Schizophrenia · NA · recruiting
NCT07261202 — Impact of Indoor Overheating on Physiological Strain in Children · NA · recruiting
NCT07267598 — Suitability of a 26 °C Indoor Environment for Mitigating Heat Strain in Young Adults · NA · recruiting
NCT07054723 — Surviving Daily Life · recruiting

Other Fundación Pública Andaluza para la gestión de la Investigación en Sevilla trials

Trials by the same sponsor.

NCT05225961 — ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem · Phase 4 · completed
NCT07521969 — Out-patiente Management for Gangrenous Acute Appendicitis: The PENDI-CSI II Randomized Clinical Trial. · NA · recruiting
NCT07153406 — Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients · Phase 3 · not yet recruiting
NCT07353424 — A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polypheno · NA · recruiting
NCT06602310 — Utility of Preanestes@s2.0, a Web Based Application for Preoperative Assessment. · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05546424 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05546424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing